Amazon Receives its Highest OPS Rating to Date from StockDiagnostics.com; OPS (Operational-Cashflow Per Share) is Now Positive for Trailing Twelve Months


NEW YORK, May 21, 2002, (PRIMEZONE) -- StockDiagnostics.com announces that it has upgraded Amazon.com, Inc. (Nasdaq:AMZN), to an OPS Rating(SM) of "3" from a previous OPS Rating of "6." This represents the highest OPS Rating to date that that Amazon has received from StockDiagnostics.com. OPS Ratings on over 7,500 companies can be found at: http://www.stockdiagnostics.com

Amazon's OPS Rating increase was justified by its recently filed Cash Flow Statements for its first quarter ending March 31, 2002, which depicted that its OPS(SM) (Operational-cashflow Per Share) for the most recent 12 months was a positive +$.12 per share. This compared to a negative OPS of -$.65 for the previous comparable 12 months ending March 31, 2001.

For information on OPS (Operational-cashflow Per Share) go to; http://www.stockdiagnostics.com/member/ops.htm

How are OPS Ratings determined?

OPS Ratings were discovered from StockDiagnostics.com's in-depth research on Operational Cash Flow. These studies revealed that a company's OPS (Operational- cashflow Per Share) logically falls into a mathematical sequence that ranks it into one of eight distinctive risk categories. Ratings are scaled 1 through 8, with number one (1), being the highest rating and number eight (8), the lowest. A "Ratings Suspended" status is given for all companies diagnosed with, The EPS Syndrome during the most recent four quarters.

For more information on OPS Ratings go to; http://www.stockdiagnostics.com/member/ops_rating.htm

For information on The EPS Syndrome go to; http://www.stockdiagnostics.com/member/eps_syndrome.htm

About StockDiagnostic.com

StockDiagnostics.com has designed and built a proprietary data refinery that automates the process of collecting, sorting, and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement and securities pricing variances or anomalies and to monitor changes in the performance of public companies.

For more information on StockDiagnostics.com. go to; http://www.stockdiagnostics.com/member/help.htm#a1

Disclaimer:

The information provided by StockDiagnostics.com does not constitute a recommendation by StockDiagnostics.com to buy, sell, or hold any security or to follow any particular trading or investment strategy. Also, the information provided should not be construed as, an offer, or a solicitation of an offer, to buy or sell securities. An Investor's best course of action must be based upon individual circumstances. StockDiagnostics.com shall not be liable for any damages or costs of any type arising out of or in any way connected with your use of our services.



            

Tags


Contact Data